Phio Pharmaceuticals Corp is a biotechnology business based in the US. Phio Pharmaceuticals shares (PHIO) are listed on the NASDAQ and all prices are listed in US Dollars. Phio Pharmaceuticals employs 10 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $0.88 |
|---|---|
| 52-week range | $0.82 - $4.36 |
| 50-day moving average | $1.25 |
| 200-day moving average | $1.84 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.13 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.8772 from 2022-01-20
| 1 week (2022-01-14) | -0.77% |
|---|---|
| 1 month (2021-12-22) | -26.29% |
| 3 months (2021-10-22) | -46.18% |
| 6 months (2021-07-22) | -53.59% |
| 1 year (2021-01-22) | -69.65% |
|---|---|
| 2 years (2020-01-22) | -91.02% |
| 3 years (2019-01-22) | 159.91% |
| 5 years (2017-01-20) | 30.24% |
| Gross profit TTM | $-4,431,000 |
|---|---|
| Return on assets TTM | -33.9% |
| Return on equity TTM | -60.43% |
| Profit margin | 0% |
| Book value | $1.87 |
| Market capitalisation | $12 million |
TTM: trailing 12 months
We're not expecting Phio Pharmaceuticals to pay a dividend over the next 12 months.
Phio Pharmaceuticals's shares were split on a 1:55 basis on 14 January 2020. So if you had owned 55 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Phio Pharmaceuticals shares – just the quantity. However, indirectly, the new 5400% higher share price could have impacted the market appetite for Phio Pharmaceuticals shares which in turn could have impacted Phio Pharmaceuticals's share price.
Over the last 12 months, Phio Pharmaceuticals's shares have ranged in value from as little as $0.821 up to $4.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Phio Pharmaceuticals's is 1.8662. This would suggest that Phio Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Phio Pharmaceuticals Corp. , a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.